The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

The BioNTech SE ADR BNTX slid 1.15% to $112.43 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 and the ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (BRSE:22UA) with a Buy recommendation. There are 447 funds or institutions ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Check the time stamp on this data. Updated AI-Generated Signals for Biontech Se (BNTX) available here: BNTX. Type a few ...